hyperlipidemia

Showing 1 - 25 of 337

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Hyperlipidemia Trial in Beijing (JS401, Placebo)

Recruiting
  • Hyperlipidemia
  • Beijing, Beijing, China
    Peking University Third Hospital
Sep 15, 2023

Cardiometabolic Disease, Hyperlipidemia Trial in Beijing (Telehealth integrated care, Conventional health care)

Recruiting
  • Cardiometabolic Disease
  • Hyperlipidemia
  • Telehealth integrated care
  • Conventional health care
  • Beijing, Beijing, China
    Peking University Third Hospital
Sep 1, 2023

Hyperlipidemia Trial in Leuven (Cholesfytol NG®) supplement)

Completed
  • Hyperlipidemia
  • Cholesfytol NG®) supplement
  • Leuven, Belgium
    Cliniques universitaires St-Luc and Institut de Recherche Expéri
Aug 18, 2023

Hyperlipidemia, Hyperglycemia, Type 2 Diabetes Trial in Taipei (Adlay with white rice, white rice)

Recruiting
  • Hyperlipidemia
  • +2 more
  • Adlay with white rice
  • white rice
  • Taipei, Taiwan
    National Taiwan University Hospital
Aug 17, 2023

Lipodystrophy, Diabetes, Hyperlipidemia Trial run by the NIDDK (Metreleptin)

Recruiting
  • Lipodystrophy
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Diabetes, Lipodystrophy, Hyperlipidemia Trial run by the NIDDK (Metreleptin)

Active, not recruiting
  • Diabetes
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 21, 2023

Lipoprotein Metabolism in Normal Volunteers and High Levels of

Completed
  • Hypolipoproteinemia
  • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Hyperlipidemia Trial in Guangzhou (SHR-1209, Placebo)

    Completed
    • Hyperlipidemia
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital ,The Second Affiliated Hospital of
    Nov 29, 2022

    Hyperlipidemia Trial in Worldwide (Evolocumab, Ezetimibe, Placebo to Evolocumab)

    Completed
    • Hyperlipidemia
    • Evolocumab
    • +6 more
    • Birmingham, Alabama
    • +243 more
    Nov 4, 2022

    Hyperlipidemia Trial in Worldwide (biological, drug, other)

    Completed
    • Hyperlipidemia
    • Evolocumab
    • +3 more
    • Birmingham, Alabama
    • +82 more
    Nov 4, 2022

    Hyperlipidemia, Mixed Dyslipidemia Trial in Denver (Evolocumab)

    Completed
    • Hyperlipidemia
    • Mixed Dyslipidemia
    • Evolocumab
    • Denver, Colorado
      Research Site
    Nov 3, 2022

    Non-surgical Periodontal Therapy on Severe Periodontitis and

    Recruiting
    • Periodontitis Chronic Generalized Severe
    • +5 more
    • non-surgical periodontal therapy
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Sep 17, 2022

    Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot

    Recruiting
    • Hyperlipidemia
    • Pregnancy
      • New York, New York
        Mount Sinai OBGYN Faculty Practice Associates
      Sep 9, 2022

      Cardiovascular Disease, Hypertension, Diabetes Trial in Boston, Philadelphia, Charleston (Unmet Need Screening, Unmet Need

      Recruiting
      • Cardiovascular Disease
      • +3 more
      • Unmet Need Screening
      • +2 more
      • Boston, Massachusetts
      • +2 more
      Aug 12, 2022

      Metabolic Syndrome and Gen-polymorphs Influence on Weightloss

      Completed
      • Childhood Obesity
      • +4 more
      • Chronic care multidisciplinary intervention of childhood obesity
      • Holbaek, Denmark
        The Children's Obesity Clinic, Paediatric Department, University
      Jul 15, 2022

      Coronary Artery Disease, Bypass Graft Stenosis, Dyslipidemias Trial (Computed tomography coronary angiogram)

      Not yet recruiting
      • Coronary Artery Disease
      • +7 more
      • Computed tomography coronary angiogram
      • (no location specified)
      May 24, 2022

      Hypercholesterolemia, Hyperlipidemia Trial in Beijing (SHR-1209 ;)

      Active, not recruiting
      • Hypercholesterolemia
      • Hyperlipidemia
      • SHR-1209 ;placebo
      • Beijing, Beijing, China
        Beijing Anzhen Hospital, Capital Medical University
      May 23, 2022

      Hyperlipidemia Trial in Shanghai (DC371739, Placebo)

      Completed
      • Hyperlipidemia
      • Shanghai, Shanghai, China
        Shanghai Xu hui Central Hospital
      Mar 15, 2022

      Hyperlipidemia Trial in Hangzhou, Shanghai (AK102, Placebo)

      Recruiting
      • Hyperlipidemia
      • AK102
      • Placebo
      • Hangzhou, Zhejiang, China
      • +1 more
      Feb 18, 2022

      Hyperlipidemia Trial in Nanchang (AK102, Placebo)

      Recruiting
      • Hyperlipidemia
      • AK102
      • Placebo
      • Nanchang, Jiangxi, China
        The Third Hospital of Nanchang
      Feb 15, 2022

      Hyperlipidemia Trial in Beijing (AK102, Placebo)

      Recruiting
      • Hyperlipidemia
      • AK102
      • Placebo
      • Beijing, China
        Peking University First Hospital
      Feb 15, 2022

      Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters:

      Completed
      • Hyperlipidemia
      • Omega-3 fatty acid ethyl esters
      • Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
      • Osaka, Japan
      • +1 more
      Dec 2, 2021

      Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

      Completed
      • Coronary Heart Disease
      • +2 more
      • (no location specified)
      Feb 7, 2022

      Hypercholesterolemia, Hyperlipidemia Trial (Vytorin + Niaspan, Vytorin, Niaspan)

      Completed
      • Hypercholesterolemia
      • Hyperlipidemia
      • Vytorin + Niaspan
      • +2 more
      • (no location specified)
      Feb 7, 2022

      Hyperlipidemia Trial (Ezetimibe, Ezetimibe/atorvastatin 10mg/10mg FDC, Atorvastatin 10mg)

      Completed
      • Hyperlipidemia
      • (no location specified)
      Feb 7, 2022